ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Free Report) rose 1.5% on Friday . The company traded as high as $1.98 and last traded at $1.98. 1,032 shares traded hands during trading, a decline of 97% from the average session volume of 37,766 shares. The stock had previously closed at $1.95.
ProMIS Neurosciences Stock Performance
The company has a market capitalization of $37.54 million, a P/E ratio of -1.75 and a beta of 0.67. The firm has a 50 day moving average price of $2.04 and a two-hundred day moving average price of $1.78.
ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.09) EPS for the quarter. On average, equities analysts expect that ProMIS Neurosciences, Inc. will post -1.11 earnings per share for the current year.
Hedge Funds Weigh In On ProMIS Neurosciences
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Articles
- Five stocks we like better than ProMIS Neurosciences
- How to Use the MarketBeat Dividend Calculator
- MarketBeat Week in Review – 4/22 – 4/26
- Investing in Travel Stocks Benefits
- 3 Stocks Leading the U.S. Agriculture Comeback
- Breakout Stocks: What They Are and How to Identify Them
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.